...
首页> 外文期刊>Journal of psychoactive drugs >Combating substance abuse with ibogaine: pre- and posttreatment recommendations and an example of successive model fitting analyses.
【24h】

Combating substance abuse with ibogaine: pre- and posttreatment recommendations and an example of successive model fitting analyses.

机译:用伊博加因对付药物滥用:治疗前和治疗后建议以及连续模型拟合分析的示例。

获取原文
获取原文并翻译 | 示例

摘要

Ibogaine is an indole alkaloid derived from the root bark of the African shrub Tabernan the iboga and it has been used for many years as a medicinal and ceremonial agent in West Central Africa. Furthermore, both anecdotal observations and recent studies suggest that ibogaine alleviates withdrawal symptoms and reduces drug cravings. Although ibogaine articles typically include information bearing on the duration of drug abstinence following treatment, little if any attention is given to the psychological and environmental factors that might facilitate a positive treatment outcome. Hence, a major purpose of the present review is to suggest a number of theory-driven, pretreatment and posttreatment recommendations that have good potential for enhancing ibogaine's effectiveness. The second major purpose of this review is to demonstrate, through a reanalysis of previously published results, the utility of conducting successive model fitting analyses on ibogaine treatment data. Such analyses are useful for determining both the strength and form of the association between pre-ibogaine treatment variables and post-ibogaine treatment outcomes. Finally, in order to facilitate future quantitative reviews, the authors recommend that a minimum set of patient- and treatment-related variables be included in all ibogaine publications involving human participants.
机译:伊博加因是一种吲哚生物碱,起源于非洲灌木塔伯南(伊塔加)的根皮,在中非西部地区已被用作药物和礼仪。此外,轶事性观察和最近的研究均表明,依博加因缓解了戒断症状并减少了对药物的渴望。尽管依博加因的文章通常都包含有关治疗后禁酒持续时间的信息,但很少或几乎没有关注可能有助于积极治疗结果的心理和环境因素。因此,本综述的主要目的是提出一些理论驱动的,治疗前和治疗后的建议,这些建议具有增强伊博加因有效性的良好潜力。这篇综述的第二个主要目的是通过对先前发表的结果进行重新分析,来证明对依博加因治疗数据进行连续模型拟合分析的实用性。此类分析可用于确定依博加因前治疗变量与依博加因后治疗结果之间关联的强度和形式。最后,为了便于将来进行定量检查,作者建议在涉及人类参与者的所有伊博加因出版物中至少包括一组与患者和治疗相关的变量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号